Michael Bachmann Selected Research

Cytokines

5/2020	Extended half-life target module for sustainable UniCAR T-cell treatment of STn-expressing cancers.
1/2019	A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR.
1/2018	Retargeting of UniCAR T cells with an in vivo synthesized target module directed against CD19 positive tumor cells.
12/2017	Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells.
9/2014	Redirection of CD4+ and CD8+ T lymphocytes via a novel antibody-based modular targeting system triggers efficient killing of PSCA+ prostate tumor cells.
7/2013	TLR7/8 agonists trigger immunostimulatory properties of human 6-sulfo LacNAc dendritic cells.
9/2012	Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8+ and CD4+ T cells.
1/2010	Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael Bachmann Research Topics

Disease

60	Neoplasms (Cancer) 06/2022 - 09/2004
13	Prostatic Neoplasms (Prostate Cancer) 04/2022 - 09/2004
6	Systemic Lupus Erythematosus (Libman-Sacks Disease) 11/2012 - 03/2005
4	Neoplasm Metastasis (Metastasis) 10/2018 - 06/2011
4	Autoimmune Diseases (Autoimmune Disease) 01/2017 - 03/2005
3	Hematologic Neoplasms (Hematological Malignancy) 04/2022 - 01/2020
3	Pheochromocytoma 01/2021 - 01/2016
3	Carcinoma (Carcinomatosis) 01/2019 - 09/2005
3	Leukemia 01/2018 - 01/2017
2	Squamous Cell Carcinoma of Head and Neck 03/2022 - 01/2020
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022 - 07/2013
2	Melanoma (Melanoma, Malignant) 03/2021 - 01/2020
2	COVID-19 01/2021 - 01/2021
2	Diabetes Mellitus 01/2021 - 08/2006
2	Disease Progression 09/2020 - 10/2018
2	Tumor Lysis Syndrome 01/2019 - 01/2018
2	Inflammation (Inflammations) 01/2016 - 10/2014
2	Psoriasis (Pustulosis Palmaris et Plantaris) 02/2013 - 03/2011
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 04/2022
1	Thrombotic Thrombocytopenic Purpura 01/2021
1	Thromboinflammation 01/2021
1	Infections 01/2021
1	Multiple Myeloma 01/2020
1	Paraganglioma (Paragangliomas) 10/2018
1	Non-Muscle Invasive Bladder Neoplasms 11/2017
1	Urinary Bladder Neoplasms (Bladder Cancer) 11/2017
1	Breast Neoplasms (Breast Cancer) 08/2017

Drug/Important Bio-Agent (IBA)

28	AntigensIBA 04/2022 - 01/2007
17	Chimeric Antigen ReceptorsIBA 04/2022 - 01/2010
14	Proteins (Proteins, Gene)FDA Link 03/2022 - 09/2004
8	CytokinesIBA 05/2020 - 01/2010
7	Peptides (Polypeptides)IBA 01/2020 - 01/2007
6	AntibodiesIBA 03/2018 - 08/2006
5	Bispecific AntibodiesIBA 09/2014 - 06/2011
5	AutoantibodiesIBA 01/2010 - 03/2005
4	Neoplasm Antigens (Tumor Antigens)IBA 03/2021 - 05/2006
4	EpitopesIBA 01/2020 - 01/2007
4	AutoantigensIBA 11/2012 - 08/2006
3	T-Cell Antigen Receptors (T-Cell Receptor)IBA 03/2021 - 01/2011
2	Immune Checkpoint InhibitorsIBA 01/2020 - 03/2018
2	Programmed Cell Death 1 ReceptorIBA 01/2020 - 03/2018
2	1- (1,3- carboxypropyl)- 4,7- carboxymethyl- 1,4,7- triazacyclononaneIBA 10/2018 - 07/2017
2	LuciferasesIBA 10/2018 - 11/2017
2	Somatostatin Receptors (Somatostatin Receptor)IBA 10/2018 - 01/2016
2	CatecholaminesIBA 10/2018 - 01/2016
2	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 07/2017 - 01/2016
2	Biological ProductsIBA 01/2016 - 02/2012
2	DNA (Deoxyribonucleic Acid)IBA 07/2015 - 08/2006
2	Toll-Like Receptors (Toll-Like Receptor)IBA 07/2013 - 03/2011
2	AndrogensIBA 06/2011 - 09/2005
2	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 05/2006 - 09/2004
1	Heavy Chain Fusion Regulatory Protein 1IBA 03/2022
1	Messenger RNA (mRNA)IBA 03/2022
1	AlbuminsIBA 01/2022
1	Cannabinoid Receptors (Cannabinoid Receptor)IBA 01/2022
1	RadiopharmaceuticalsIBA 01/2022
1	Ghrelin ReceptorsIBA 03/2021
1	GhrelinIBA 03/2021
1	endothelial PAS domain-containing protein 1IBA 01/2021
1	von Willebrand FactorIBA 01/2021
1	Granzymes (Granzyme)IBA 01/2021
1	FurinIBA 01/2021
1	MicroRNAs (MicroRNA)IBA 09/2020
1	bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amineIBA 06/2020
1	CarbohydratesIBA 05/2020
1	Artificial ReceptorsIBA 01/2020
1	Therapeutic UsesIBA 01/2020
1	cyclopropapyrroloindoleIBA 01/2020
1	Growth Factor ReceptorsIBA 01/2020
1	PSMA-11IBA 01/2019
1	thiocyanateIBA 10/2018
1	Epinephrine (Adrenaline)FDA LinkGeneric 10/2018
1	3-methoxytyramine (methoxytyramine)IBA 10/2018
1	Dopamine (Intropin)FDA LinkGeneric 10/2018
1	MetanephrineIBA 10/2018
1	Norepinephrine (Noradrenaline)FDA LinkGeneric 10/2018
1	NormetanephrineIBA 10/2018
1	B7-H1 AntigenIBA 03/2018
1	CTLA-4 AntigenIBA 03/2018
1	ErbB Receptors (EGF Receptor)IBA 11/2017
1	Lysine (L-Lysine)FDA Link 11/2017
1	TrypsinIBA 11/2017
1	Biomarkers (Surrogate Marker)IBA 08/2017
1	Chelating AgentsIBA 07/2017
1	Acetic Acid (Vinegar)FDA LinkGeneric 05/2017
1	Diphosphonates (Bisphosphonates)IBA 05/2017
1	Voltage-Gated Potassium Channels (Voltage-Gated Potassium Channel)IBA 01/2017
1	HydrogelsIBA 09/2016

Therapy/Procedure

23	Therapeutics 04/2022 - 06/2007
12	Immunotherapy 06/2022 - 09/2004
5	Precision Medicine 01/2019 - 01/2016
2	Radiotherapy 01/2021 - 01/2020
1	Chemoradiotherapy 03/2022
1	Cell- and Tissue-Based Therapy (Cell Therapy) 03/2021
1	Investigational Therapies (Experimental Therapy) 03/2021
1	Plasma Exchange 01/2021
1	Radioimmunotherapy 01/2020
1	Cell Transplantation 01/2020
1	Intravenous Injections 10/2018
1	Catheters 11/2017